Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$29M | — | — | 757.0% | -379.3% | -$20M | — | $5M |
| 2024 | — | -$23M | — | — | -691.1% | -169.8% | -$20M | — | $11M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$9M | — | — | 153.1% | -123.1% | -$8M | — | $4M |
| Mar '26 | — | -$9M | — | — | 180.2% | -113.3% | -$7M | — | $5M |
| Jun '25 | — | -$5M | — | — | -142.7% | — | -$4M | — | — |
| Mar '25 | — | -$5M | — | — | -126.5% | — | -$5M | — | — |
See the revenue and net-income charts above for ONCOLYTICS BIOTECH INC's multi-year trend.
As of FY2025, ONCOLYTICS BIOTECH INC reported — of total debt against $5M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.